Request to Consolidate Levaquin Achilles Tendon Suits for Trial Denied Again

A federal judge has once again denied plaintiffs’ request to have a consolidated trial for several Levaquin suits, which all contain similar allegations that the antibiotic causes tendon damage. 

In the federal Levaquin litigation, six cases have been designated for early trials, known as bellwether cases, to help gauge how juries will respond to evidence and testimony that is likely to be presented in hundreds of other similar Levaquin suits.

In December, U.S. District Judge John R. Tunheim rejected a request to consolidate some of the first cases into one trial, indicating that it was premature to make such a determination, as additional information was needed about the facts of each case and the issues to be presented at trial.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Following a hearing last Friday, Judge Tunheim denied the renewed Motion to Consolidate three Levaquin achilles tendon damage claims. Therefore, a series of individual trials will be held.

Plaintiffs had proposed that claims brought by Calvin Christensen, Rickard Kirkes and John Schedin be combined for one jury trial, as the cases involve substantial similarities. All of the plaintiffs are males over the age of 70 who suffered Achilles tendinitis, Achilles tendon rupture or both after being prescribed the same dose of Levaquin to treat a respiratory infection. They were also each prescribed a concomitant corticosteroid, suffered the Achilles tendon injury from Levaquin while still on the drug and the warnings at the time of each prescription were practically identical.

Attorneys for the drug maker argued that the plaintiffs failed to show how consolidating the cases would be more efficient and benefit the judicial process. They also said that there remained significant factual differences in the cases, which required that consolidation be denied.

Levaquin (levofloxacin) is part of a class of medications known as fluoroquinolones, which was approved by the FDA in December 1996. It is prescribed to prevent infection by stopping the reproduction of bacteria. However, it has also been found to be toxic to the tendons, leading to an increased risk of tendon damage, including debilitating ruptures of the Achilles tendon.

All lawsuits over Levaquin tendon problems filed in various federal district courts throughout the United States are centralized before Judge Tunheim for pretrial litigation as part of the MDL. The cases involve allegations that the drug maker failed to adequately warn about the increased risk of tendon ruptures and other tendon injuries that can occur from side effects of Levaquin.


  • MikeJune 7, 2010 at 9:33 pm

    Levaquin is a poison!! It totally ruined my life and NEEDS to be recalled. I can't believe that it is still legal to be prescribed in the US. I took two pills and am left with Tinnitus, Hyperacusis, depression and major anxiety. I am not the same person that I was before taking this poison. I would prefer death over how I have felt since taking Levaquin.

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

More Than 1,200 Valsartan Lawsuits Pending in MDL Over Cancers Caused By Recalled Blood Pressure Drug
More Than 1,200 Valsartan Lawsuits Pending in MDL Over Cancers Caused By Recalled Blood Pressure Drug (Posted today)

Plaintiffs and defendants have briefed the new incoming judge on the status of more than 1,200 Valsartan lawsuits ahead of a meeting later this month, which seeks to begin moving the litigation forward following the retirement of the preceding presiding judge.

BioZorb Lawsuit Alleges Breast Tissue Marker Failed, Requiring Surgical Removal
BioZorb Lawsuit Alleges Breast Tissue Marker Failed, Requiring Surgical Removal (Posted 4 days ago)

A BioZorb lawsuit has been filed by several breast cancer survivors after the BioZorb implants moved out of place and failed to dissolve int he body, requiring surgical removal.